Last reviewed · How we verify
Moxifloxacin or Levofloxacin
Moxifloxacin or Levofloxacin is a fluoroquinolone Small molecule drug developed by UMC Utrecht. It is currently in Phase 3 development for Community-acquired pneumonia, Skin and skin structure infections.
Moxifloxacin and Levofloxacin are broad-spectrum antibiotics that inhibit DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication.
Moxifloxacin and Levofloxacin are broad-spectrum antibiotics that inhibit DNA gyrase and topoisomerase IV, enzymes critical for bacterial DNA replication. Used for Community-acquired pneumonia, Skin and skin structure infections.
At a glance
| Generic name | Moxifloxacin or Levofloxacin |
|---|---|
| Sponsor | UMC Utrecht |
| Drug class | fluoroquinolone |
| Target | DNA gyrase and topoisomerase IV |
| Modality | Small molecule |
| Therapeutic area | Infectious Diseases |
| Phase | Phase 3 |
Mechanism of action
By inhibiting these enzymes, moxifloxacin and levofloxacin prevent bacterial DNA replication and transcription, ultimately leading to bacterial cell death. This mechanism is effective against a wide range of bacteria, including both Gram-positive and Gram-negative species.
Approved indications
- Community-acquired pneumonia
- Skin and skin structure infections
Common side effects
- Nausea
- Diarrhea
- Vomiting
- Headache
- Dizziness
Key clinical trials
- Oral Antimicrobial Treatment vs. Outpatient Parenteral for Infective Endocarditis (PHASE4)
- A Platform Trial for Gram Negative Bloodstream Infections (NA)
- A Phase 2b Clinical Study of JDB0131 Benzenesulfonate Tablets (PHASE2)
- Pharmacokinetic Study of Antiretroviral Drugs and Related Drugs During and After Pregnancy
- Pharmacokinetic Properties of Antiretroviral and Anti-Tuberculosis Drugs During Pregnancy and Postpartum
- Comparing Oral Versus Parenteral Antimicrobial Therapy (PHASE4)
- A Study of Fluoroquinolones Exposure and Collagen-Related Serious Adverse Events
- Innovating(IN) Shorter(S), All- Oral, Precised(P), Individualized(I) Treatment Regimen(RE) for Rifampicin Resistant Tuberculosis(INSPIRE-TB) (PHASE3)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Moxifloxacin or Levofloxacin CI brief — competitive landscape report
- Moxifloxacin or Levofloxacin updates RSS · CI watch RSS
- UMC Utrecht portfolio CI
Frequently asked questions about Moxifloxacin or Levofloxacin
What is Moxifloxacin or Levofloxacin?
How does Moxifloxacin or Levofloxacin work?
What is Moxifloxacin or Levofloxacin used for?
Who makes Moxifloxacin or Levofloxacin?
What drug class is Moxifloxacin or Levofloxacin in?
What development phase is Moxifloxacin or Levofloxacin in?
What are the side effects of Moxifloxacin or Levofloxacin?
What does Moxifloxacin or Levofloxacin target?
Related
- Drug class: All fluoroquinolone drugs
- Target: All drugs targeting DNA gyrase and topoisomerase IV
- Manufacturer: UMC Utrecht — full pipeline
- Therapeutic area: All drugs in Infectious Diseases
- Indication: Drugs for Community-acquired pneumonia
- Indication: Drugs for Skin and skin structure infections
- Compare: Moxifloxacin or Levofloxacin vs similar drugs
- Pricing: Moxifloxacin or Levofloxacin cost, discount & access